Evidence map›Paper›PMID 32909144›Full record

ArticlePharmacoEconomics2020

The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?

David G T Whitehurst, John E Brazier, Rosalie Viney, Brendan J Mulhern

Abstract read
PubMed Publisher
In one paragraph

Article in PharmacoEconomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  2. The Short Form 6 Dimensions (SF-6D): Development and Evolution.Applied health economics and health policy · 2025
    Review
  3. Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Article
  4. Population Norms for SF-6Dv2 and EQ-5D-5L in China.Applied health economics and health policy · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

David G T WhitehurstFaculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada. david_whitehurst@sfu.ca.ORCID http://orcid.org/0000-0002-7890-6756
John E BrazierHealth Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK.ORCID http://orcid.org/0000-0001-8645-4780
Rosalie VineyCentre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-0039-9635
Brendan J MulhernCentre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-3656-8063

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Quality of LifeHumansPsychometricsQuality-Adjusted Life YearsSurveys and Questionnaires

Identifiers

PMID32909144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.